HistoRx Inc. has landed a big boost for its cancer prognosis methods from the U.S. Patent and Trademark Office, as the New Haven, Conn.-based diagnostics firm was granted an exclusive license to its cancer treatment patent.
The company said the claims issued in the patent pertains to the quantification of an enzyme in the sub-cellular compartments of tumor cells. Oncologists use these tissue biomarkers to characterize a patient’s cancer and personalize their treatment by predicting which drugs will work best for them.
The patent holders are Yale University and inventors David Rimm, Bob Camp, Mark Gustavson and Greg Tedeschi.
HistoRx Inc. landed a $1.5 million loan from the state’s quasi-public life sciences initiative.